These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7917773)

  • 1. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.
    Holford NH; Guentert TW; Dingemanse J; Kettler R
    Br J Clin Pharmacol; 1994 Jun; 37(6):553-7. PubMed ID: 7917773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
    Dingemanse J; Wood N; Jorga K; Kettler R
    Br J Clin Pharmacol; 1997 Jan; 43(1):41-7. PubMed ID: 9056051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
    Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
    Henriot S; Kuhn C; Kettler R; Da Prada M
    J Neural Transm Suppl; 1994; 41():321-5. PubMed ID: 7931245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.
    Guentert TW; Holford NH; Pfefen JP; Dingemanse J
    Br J Clin Pharmacol; 1994 Jun; 37(6):545-51. PubMed ID: 7917772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
    Mason RP; Olmstead EG; Jacob RF
    Biochem Pharmacol; 2000 Sep; 60(5):709-16. PubMed ID: 10927030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    Bench CJ; Price GW; Lammertsma AA; Cremer JC; Luthra SK; Turton D; Dolan RJ; Kettler R; Dingemanse J; Da Prada M
    Eur J Clin Pharmacol; 1991; 40(2):169-73. PubMed ID: 1906004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course.
    Kettler R; Cesura AM; Dingemanse J; Da Prada M
    J Neural Transm Suppl; 1990; 32():211-4. PubMed ID: 2089093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
    Zhou S; Chen G; Huang G
    Bioorg Med Chem; 2018 Sep; 26(17):4863-4870. PubMed ID: 30143367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y; Inoue T; Nakagawa S; Boku S; Izumi T; Koyama T
    Eur J Pharmacol; 2010 Jul; 637(1-3):77-82. PubMed ID: 20406628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.
    Galva MD; Bondiolotti GP; Olasmaa M; Picotti GB
    J Neural Transm Gen Sect; 1995; 101(1-3):83-94. PubMed ID: 8695059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic and region-specific MAO-B response to aging in normal human brain.
    Saura J; Andrés N; Andrade C; Ojuel J; Eriksson K; Mahy N
    Neurobiol Aging; 1997; 18(5):497-507. PubMed ID: 9390776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
    Thébault JJ; Guillaume M; Levy R
    Pharmacotherapy; 2004 Oct; 24(10):1295-305. PubMed ID: 15628826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.
    Berlin I; Aubin HJ; Pedarriosse AM; Rames A; Lancrenon S; Lagrue G;
    Addiction; 2002 Oct; 97(10):1347-54. PubMed ID: 12359039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The density of monoamine oxidase B sites is not altered in the postmortem brain of alcoholics.
    Maeztu AI; Ballesteros J; Callado LF; Gutiérrez M; Meana JJ
    Alcohol Clin Exp Res; 1997 Nov; 21(8):1479-83. PubMed ID: 9394121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974A in normal volunteers.
    Hinze C; Harland D; Zreika M; Dulery B; Hardenberg J
    J Neural Transm Suppl; 1990; 32():203-9. PubMed ID: 2089092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.